Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

M.G. Bousser; P. Amarenco; A. Chamorro; M. Fisher; I. Ford; K. Fox; M. Hennerici; H.P. Mattle; L.J. Kappelle; P.M. Rothwell

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

Translated title of the contribution: Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

M.G. Bousser
, P. Amarenco
, A. Chamorro
, M. Fisher
, I. Ford
, K. Fox
, M. Hennerici
, H.P. Mattle
, L.J. Kappelle
, P.M. Rothwell

Neurology & Neurosurgery

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
Original language	Undefined/Unknown
Pages (from-to)	509-518
Number of pages	10
Journal	Cerebrovascular Diseases
Volume	27
Issue number	5
Publication status	Published - 2009

Cite this

Bousser, M. G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K., Hennerici, M., Mattle, H. P., Kappelle, L. J., & Rothwell, P. M. (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular Diseases, 27(5), 509-518.

Bousser, M.G. ; Amarenco, P. ; Chamorro, A. et al. / Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. In: Cerebrovascular Diseases. 2009 ; Vol. 27, No. 5. pp. 509-518.

@article{b53a7d2958cf4aa5bdb3e1c8cb498b41,

title = "Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study",

author = "M.G. Bousser and P. Amarenco and A. Chamorro and M. Fisher and I. Ford and K. Fox and M. Hennerici and H.P. Mattle and L.J. Kappelle and P.M. Rothwell",

year = "2009",

language = "Undefined/Unknown",

volume = "27",

pages = "509--518",

journal = "Cerebrovascular Diseases",

issn = "1015-9770",

publisher = "S. Karger AG",

number = "5",

}

Bousser, MG, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, M, Mattle, HP, Kappelle, LJ & Rothwell, PM 2009, 'Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study', Cerebrovascular Diseases, vol. 27, no. 5, pp. 509-518.

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. / Bousser, M.G.; Amarenco, P.; Chamorro, A. et al.
In: Cerebrovascular Diseases, Vol. 27, No. 5, 2009, p. 509-518.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

AU - Bousser, M.G.

AU - Amarenco, P.

AU - Chamorro, A.

AU - Fisher, M.

AU - Ford, I.

AU - Fox, K.

AU - Hennerici, M.

AU - Mattle, H.P.

AU - Kappelle, L.J.

AU - Rothwell, P.M.

PY - 2009

Y1 - 2009

M3 - Article

SN - 1015-9770

VL - 27

SP - 509

EP - 518

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

IS - 5

ER -

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K et al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular Diseases. 2009;27(5):509-518.